12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333+RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS

被引：42
|
作者：
Poordad, F. [1 ]
Lawitz, E. [2 ]
Kowdley, K. V. [3 ]
Everson, G. T. [4 ]
Freilich, B. [5 ]
Cohen, D. [6 ]
Siggelkow, S. [6 ]
Heckaman, M. [6 ]
Menon, R. [6 ]
Pilot-Matias, T. [6 ]
Podsadecki, T. [6 ]
Bernstein, B. [6 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Alamo Med Res, San Antonio, TX USA
[3] Virginia Mason Med Ctr, Digest Dis Inst, Seattle, WA 98101 USA
[4] Univ Colorado Denver & Hosp, Aurora, CO USA
[5] Kansas City Gastroenterol & Hepatol, Kansas City, MO USA
[6] Abbott, Abbott Pk, IL USA
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61410-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1399
引用
收藏
页码：S549 / S550
页数：2
相关论文
共 34 条
  • [21] TURQUOISE-II: Regimens of ABT-450/r/Ombitasvir and Dasabuvir With Ribavirin Achieve High SVR12 Rates in HCV Genotype 1-Infected Patients with Cirrhosis, Regardless of Baseline Characteristics
    Fried, Michael W.
    Forns, Xavier
    Reau, Nancy
    Wedemeyer, Heiner
    Shiffman, Mitchell L.
    Castro, Angeles
    Mutimer, David J.
    Lee, Samuel S.
    Trinh, Roger
    Lovell, Sandra S.
    Canizaro, Leticia
    Pedrosa, Marcos
    Berg, Thomas
    HEPATOLOGY, 2014, 60 : 238A - 238A
  • [22] 4-WEEK VIROLOGIC RESPONSE AND SAFETY OF ABT-450 GIVEN WITH LOW-DOSE RITONAVIR (ABT-450/R) IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN (SOC) AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAiVE SUBJECTS
    Lawitz, Eric
    Gaultier, Isabelle
    Poordad, Fred
    DeJesus, Edwin
    Kowdley, Kris V.
    Sepulveda, Gladys
    Cohen, Daniel E.
    Menon, Rajeev
    Larsen, Lois M.
    Podsadecki, Thomas J.
    Bernstein, Barry
    HEPATOLOGY, 2010, 52 (04) : 878A - 879A
  • [23] TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV)
    Kowdley, Kris V.
    Poordad, Fred
    Trinh, Roger
    Hezode, Christophe
    Zeuzem, Stefan
    Agarwal, Kosh
    Shiffman, Mitchell L.
    Wedemeyer, Heiner
    Berg, Thomas
    Yoshida, Eric M.
    Forns, Xavier
    Lovell, Sandra S.
    DaSilva-Tillmann, Barbara
    Campbell, Andrew L.
    Podsadecki, Thomas
    GASTROENTEROLOGY, 2014, 146 (05) : S903 - S903
  • [24] ABT-267 COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12 WEEK ANTIVIRAL AND SAFETY ANALYSIS
    Sullivan, G. J.
    Rodriques-Torres, M.
    Lawitz, E.
    Poordad, F.
    Kapoor, M.
    Campbell, A.
    Setze, C.
    Xie, W.
    Khatri, A.
    Dumas, E.
    Krishnan, P.
    Pilot-Matias, T.
    Williams, L.
    Bernstein, B.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S480 - S480
  • [25] Interferon-Free Regimens of Abt-450/R, Abt-267, Abt-333, and Ribavirin Achieve High Sustained Virologic Response 4 Weeks Post-Treatment (SVR4) Rates in Patients With Chronic HCV Genotype 1 Regardless of Race, Ethnicity, or Other Baseline Characteristics
    Rodriguez-Torres, Maribel
    Nunes, Frederick
    Cohen, Daniel
    Xie, Wangang
    Marincic, Christal
    Khatri, Amit
    Pilot-Matias, Tami
    Podsadecki, Thomas
    Bernstein, Barry
    GASTROENTEROLOGY, 2013, 144 (05) : S949 - S949
  • [26] TURQUOISE-II: SVR12 RATES OF 92-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV)
    Poordad, F.
    Hezode, C.
    Trinh, R.
    Kowdley, K. V.
    Zeuzem, S.
    Agarwal, K.
    Shiffman, M. L.
    Wedemeyer, H.
    Berg, T.
    Yoshida, E. M.
    Forns, X.
    Lovell, S. S.
    Da Silva-Tillmann, B.
    Campbell, A. L.
    Podsadecki, T.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S523 - S523
  • [27] A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1
    Lawitz, Eric
    Poordad, Fred
    Kowdley, Kris V.
    Cohen, Daniel E.
    Podsadecki, Thomas
    Siggelkow, Sara
    Larsen, Lois
    Menon, Rajeev
    Koev, Gennadiy
    Tripathi, Rakesh
    Pilot-Matias, Tami
    Bernstein, Barry
    JOURNAL OF HEPATOLOGY, 2013, 59 (01) : 18 - 23
  • [28] AN INTERFERON- AND RIBAVIRIN-FREE 12-WEEK REGIMEN OF ONCE-DAILY VX-135 AND DACLATASVIR IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 HCV INFECTION
    Gane, E.
    Stedman, C.
    Garg, V.
    George, S.
    Kieffer, T.
    Krop, J.
    Lawal, A.
    Lan, L.
    Rubin, R.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S528 - S529
  • [29] SVR4 and SVR12 with an interferon-free regimen of BI201335 and BI207127, ± ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: interim results of SOUND-C2
    Zeuzem, Stefan
    Gane, Ed
    Roberts, Stuart
    Mensa, Federico
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 182 - 182
  • [30] SVR4 AND SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2
    Zeuzem, S.
    Soriano, V.
    Asselah, T.
    Bronowicki, J. -P.
    Lohse, A.
    Muellhaupt, B.
    Schuchmann, M.
    Bourliere, M.
    Buti, M.
    Roberts, S.
    Gane, E.
    Stern, J. O.
    Kukolj, G.
    Dai, L.
    Boecher, W. O.
    Mensa, F. J.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S45 - S45
1234